Financial reports
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
12 Aug 21
10-Q
2021 Q1
Quarterly report
13 May 21
10-K
2020 FY
Annual report
18 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
13 Aug 20
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Jan 23
8-K
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
17 Jan 23
8-K
Viveve Announces Completion of Pivotal U.S. PURSUIT Trial
15 Dec 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Dec 22
8-K
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
1 Dec 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Nov 22
8-K
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10 Nov 22
8-K
Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
4 Oct 22
8-K
New branding reflects Company’s vision to be the leader in the treatment of Stress Urinary Incontinence in Women
27 Sep 22
8-K
Viveve to Participate in Ladenburg Thalmann Healthcare Conference
22 Sep 22
Registration and prospectus
15-12G
Securities registration termination
6 Feb 23
RW
Registration withdrawal request
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
Proxies
DEF 14A
Definitive proxy
17 Mar 22
DEFA14A
Additional proxy soliciting materials
16 Jun 21
DEFA14A
Additional proxy soliciting materials
2 Jun 21
DEFA14A
Additional proxy soliciting materials
11 May 21
DEF 14A
Definitive proxy
31 Mar 21
DEFA14A
Additional proxy soliciting materials
29 Jun 20
DEF 14A
Definitive proxy
18 May 20
PRE 14A
Preliminary proxy
6 May 20
DEF 14A
Definitive proxy
19 Aug 19
PRE 14A
Preliminary proxy
9 Aug 19
Other
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
29 Sep 22
CORRESP
Correspondence with SEC
26 Sep 22
UPLOAD
Letter from SEC
12 Jul 21
Ownership
4
Steven L Basta
5 Jan 23
4
Scott Durbin
5 Jan 23
4
DEBORA JORN
5 Jan 23
4
Arlene Morris
5 Jan 23
4
Sharon Collins Presnell
5 Jan 23
4
Jim B Robbins
5 Jan 23
SC 13G/A
Hudson Bay Capital Management LP
4 Feb 22
SC 13G/A
Empery Asset Management, LP
18 Jan 22
4
DEBORA JORN
6 Jan 22
4
Arlene Morris
6 Jan 22